Skip to content
2000
Volume 14, Issue 28
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Non-invasive detection of tumor hypoxia using radiolabeled 2-nitroimidazoles has been a major effort during the last two decades. Recent years have witnessed the introduction of several new compounds which are chemically related to [18F]fluoromisonidazole (FMISO) but show slight but distinct differences in biodistribution and metabolic clearance. Although [18F]FMISO has shown clinical potential it suffers from suboptimal oxygen dependent tissue contrast and newer agents seek to improve this essential feature. The limited data on other interesting tracers keeps the investigators busy at demonstrating the potential advantages over [18F]FMISO while efforts should start to concentrate on proving the clinical significance of such techniques in the form of outcome data from image-guided therapy modification. We review here our experiences with two hypoxia-avid agents [18F]fluoroerythronitromidazole (FETNIM) and [18F] 2-(2-nitro-1-Himidazol- 1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide (EF5) and focus on the similarities and differences of these two tracers in comparison to other radiolabeled 2-nitroimidazoles. It is recognized that only [18F]FMISO has thus far shown clinical utility and newer tracers need to be tested against this circumstance.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/138161208786404380
2008-10-01
2025-05-08
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/138161208786404380
Loading

  • Article Type:
    Research Article
Keyword(s): 2-nitroimidazoles; Hypoxia; PET; radionuclide imaging
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test